Funding Will Advance Xeltis’ aXess Device United States Regulatory and Commercial Pathway

August 4, 2026—Xeltis, a Netherlands-based developer of implants that enable the natural creation of living and long-lasting vessels, announced that it had raised an additional €20.5 million of new funding from new and existing shareholders. Participating investors included the European Innovation Council, Invest-NL, VI Partners, EQT Life Sciences, DaVita and other current shareholders, alongside Horizon 3 Healthcare, a new investor who led the round, noted the company.

According to the Xeltis, combined with the €50 million secured in 2025 from the European Investment Bank and existing shareholders, the additional financing strengthens the company’s ability to execute on its clinical, regulatory, and commercial objectives.

As outlined in the press release, the proceeds will be used to finalize the ongoing United States pivotal trial of the company’s aXess living vascular access solution for hemodialysis; to prepare for a submission to the FDA; and to support market commercialization in the United States. Xeltis announced in late 2024 that the first patient was enrolled in the ongoing aXess United States pivotal trial, which now exceeds 50% enrollment.

In July 2026, the company announced the start of the European commercialization of aXess vascular access device for patients requiring hemodialysis.

Additionally, the company advised that the funding will enable the European commercial rollout of aXess; the upscaling of the company’s manufacturing capabilities; and the continued advancement of the Xeltis peripheral artery disease (XPAD) bypass conduit clinical program, including the XPAD bypass conduit early feasibility study and the XPAD European feasibility study; and the Xeltis coronary artery bypass graft (XABG) program, including the XABG first-in-human study.